#ASH24: Relapsed/refractory multiple myeloma

Stay up to date with the latest developments in multiple myeloma from the 66th ASH Annual Meeting and Exposition, December 7–10, 2024, San Diego, US. Catch up with our live social media relating to relapsed/refractory multiple myeloma here.  

CONGRESS | #ASH24 | @DrRakeshPopat @uclh discusses the MRD negativity rates observed in the CARTITUDE-4 trial of cilta-cel for len-refractory #MultipleMyeloma. In MRD evaluable pts, MRDx10^-5 neg 89%, MRDx10^-6 neg 85.6%, sustained MRDx10^-5 neg at ≥12mo 51.7%. These data… pic.twitter.com/Qh9WflwaxF

— Multiple Myeloma Hub (@MM_Hub) December 12, 2024

CONGRESS | #ASH24 | Ciara Louise Freeman @freemanlciaraMD @MoffittNews presents the preliminary results from the IMMagine-1 trial of anito-cel for RRMM. ORR 97%, ≥CR 62%, MRD neg rate 93.1%, 12mo PFS 78.5%, 12mo OS 96.5%, any grade CRS 83%, ICANS 9%. Responses were deep and… pic.twitter.com/D1NhOeC3H8

— Multiple Myeloma Hub (@MM_Hub) December 12, 2024

CONGRESS | #ASH24 | Eyal Lebel @Hadassah_Med shares data of HBI0101, a BCMA CAR-T, for RRMM. ORR 92%, ≥CR 64%, MRD neg 74%, fresh CAR-T ORR 91%, frozen CAR-T ORR 92%, median PFS 13.5mo, median OS NR. These data support further investigation of CAR-T production in academic… pic.twitter.com/GeL6g0khZ2

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Hang Quach @HangQuach1 @StVincentsMelb shares the first results of the phase I trial of ISB 2001, a trispecific antibody, for RRMM. DL1-7 ORR 75%, DL3-7 ORR 83%, highest ORR observed in patients naïve to CAR-T and bsAb 90%. No DLTs observed up to 1200µg/kg QW.… pic.twitter.com/XYi9DO1ZHr

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Irwindeep Sandhu @UAlberta shares updates results from the CC-92480-MM-002 trial of mezigdomide in combination with dexamethasone and bortezomib or carfilzomib for RRMM. Promising efficacy data was observed in both combinations at all dose levels tested. There… pic.twitter.com/hwfDxJ2IKy

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Emma Searle @DrEmmaSearle @TheChristieNHS discusses the tolerability and clinical activity of inobrodib (CCS1477) in combination with Pom-Dex (InoPd) for RRMM. ORR 49%, median DoR 6.3mo. In the highest dose cohort ORR 75%, median DoR 9.7mo. No new safety… pic.twitter.com/yPOdvBfAjM

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Joshua Richter @JoshuaRichterMD @IcahnMountSinai shares updated results from the Phase I study of fixed-duration cevostamab, at 160mg TD level, in heavily pretreated RRMM. ORR 44.3%, prior BCMA-DT ORR 32.3%, no prior BCMA-DT ORR 60.6%, Gr ≥3 infection 19.2%,… pic.twitter.com/2R2IdY0Abd

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Andrew Kowalski @SylvesterCancer shares data for tocilizumab prophylaxis in patients with RRMM treated with teclistamab, elranatamab, or talquetamab. Tocilizumab was effective at reducing CRS, at a CRS rate of 14% compared to 56.3% with elran, 72.1% with tec,… pic.twitter.com/uJWfjakDDM

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Binod Dhakal @bhemato @MedicalCollege discusses talquetamab as a bridging therapy to BCMA-directed CAR T-cell therapy in RRMM. In HR pts ORR 62%, ≥CR 18%, median PFS 13-mo, median OS NR, 85% proceeded to receive CAR-T. Talquetamab may be a feasible choice for… pic.twitter.com/VwO7vG5nDF

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Susan Bal @SusanBal9 @UABNews shares extended FU data from the Phase I study of arlo-cel (BMS-986393) in heavily pretreated RRMM. ORR 87%, CR 53%, 150x10^6 CAR T cells ORR 91%, median DoR 18-mo, median PFS 18.3-mo, 12-mo OS 90%.
Follow our live feed for more… pic.twitter.com/f7Y0bV3hDO

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Bruno Paiva @BrunoPaiva_UNAV @unav discusses the biological and clinical significance of endogenous and CAR T cell immune profiling in RRMM; concluding that there is a need for additional immune profiling for pts treated with CAR-T to improve understanding of… pic.twitter.com/6bBrOHpz9i

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Danai Dima @DimaDanai Cleveland Clinic Taussig Cancer Institute discusses the outcomes associated with teclistamab in RRMM with prior exposure to BCMA-directed therapies in the U.S. ORR in pts with prior BCMA 48.7% vs 61.5% without prior BCMA exposure. ORR… pic.twitter.com/iBCpYEKrkb

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Doris K. Hansen @MoffittNews shares a comprehensive analysis of pre-treatment biomarkers associated with response and toxicity to ide-cel in RRMM. Pretreatment disease burden and inflammation increase ICANS risk, while higher cell doses correlate with severe… pic.twitter.com/cXbiRKaE2u

— Multiple Myeloma Hub (@MM_Hub) December 11, 2024

CONGRESS | #ASH24 | Kai Rejeski @KRejeski @MSKCancerCenter discusses pre-apheresis prediction of response and toxicity for pts receiving BCMA-targeted CAR-T for RRMM. High pre-apheresis HT scores are linked to poor-risk features, and combining these scores with MM-specific HR… pic.twitter.com/4Spttp2Wc4

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | POSTER

Caitlin Costello @Ccostello7, UCSD Moores Cancer Center, shares results from the optimized lymphodepletion cohort (N = 21) of a phase I study of P-BCMA-ALLO1, a BCMA-directed CAR-T in RRMM.

P-BCMA-ALLO1 demonstrates a promising ORR and favorable… pic.twitter.com/CVjYIj4lbB

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | POSTER

Michael Bishop @mrbishop_UC_BMT, University of Chicago, shares efficacy and safety data with 34-month median follow-up findings from a phase I study of anitocabtagene autoleucel for the treatment of patients with RRMM (N = 38).

At a longer median… pic.twitter.com/pce4tgStkC

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | POSTER

Shebli Atrash @AtrashShebli, Levine Cancer Institute, shares final results from a phase I trial of belantamab mafodotin combined with carfilzomib, lenalidomide, and dexamethasone for MM after one to three prior LOT (N = 19).

The MTD of belantamab was… pic.twitter.com/vMjwyqBe0I

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | POSTER

H. Miles Prince, Epworth HealthCare and University of Melbourne, shares long-term data on the efficacy and safety of less frequent dosing of elranatamab in patients with RRMM (N = 123) from the phase II MagnetisMM-3 study.

Elranatamab continues to… pic.twitter.com/fcXrthG0CB

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | POSTER

Niels van de Donk, Amsterdam University Medical Center, shares findings from an analysis of repeat step-up dosing and CRS events following prolonged dosing intervals of teclistamab in the phase I/II Majestec-1 study (N = 165).

These analyses show that… pic.twitter.com/p3b2bMg6gq

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | POSTER

Meral Beksac @mbeksac56, Ankara Liv Hospital, presents a post hoc subgroup analysis of a subset of patients with RRMM receiving second line belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs pomalidomide + bortezomib + dexamethasone (PVd)… pic.twitter.com/UlXqwrqEUO

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | Vania Hungria @dra_v_hungria Clínica São Germano presents an OS analysis and updated efficacy data from DREAMM-7. For BVd and DVd respectively, 36-mo OS 74% and 60%, median PFS2 NR and 33.4 mo, ORR 83.1% and 71.3%, ≥CR and MRD neg 25.1% and 10.4%.
Follow our… pic.twitter.com/bAUbopobcc

— Multiple Myeloma Hub (@MM_Hub) December 10, 2024

CONGRESS | #ASH24 | Luciano J. Costa @End_myeloma @UABDeptMed shares the preliminary results from the CA057-003 trial of mezigdomide combinations with tazemetostat, BMS-986158, and trametinib for RRMM. There were no new safety signals, neutropenia was the most common Grade 3/4… pic.twitter.com/m98BFmpoiL

— Multiple Myeloma Hub (@MM_Hub) December 9, 2024

CONGRESS | #ASH24 | Cesar Rodriguez @myelomatips @IcahnMountSinai discusses data from arm C of the Kilimanjaro study of etentamig (ABBV-383) in combination with daratumumab and dexamethasone for RRMM. At the 40-60mg dose, ORR was ~83% and CRS 29%. Further investigation is… pic.twitter.com/ENbTmqyMRx

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | Anita D'Souza @MedicalCollege shares data from a pooled analysis of MajesTEC-2 cohort a and TRIMM-2 studies of teclistamab, daratumumab, and pomalidomide in RRMM; concluding that this combination is feasible with an ORR of 85.2% and ≥CR 59.3%. In patients… pic.twitter.com/tNrHuyHdJu

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION
Daisuke Ikeda, Kameda Medical Center and Okayama University Hospital, shares findings from a single center retrospective analysis investigating whether soluble BCMA levels correlated with disease burden and its utility for disease monitoring in… pic.twitter.com/0dNgunykJB

— Multiple Myeloma Hub (@MM_Hub) December 8, 2024

CONGRESS | #ASH24 | Heloise Cheruvalath @hcheruvalath @MedicalCollege shares data on the effects of IVIG on infections in patients treated with teclistamab. The use of IVIG was associated with a reduction in infections and an increase in OS. The use of tocilizumab for CRS was… pic.twitter.com/KVmrIfYHPN

— Multiple Myeloma Hub (@MM_Hub) December 7, 2024

CONGRESS | #ASH24 | Ciara Louise Freeman @MoffittNews discusses the genomic determinants of resistance to BCMA-directed CAR-T in RRMM, including genomic complexity, upregulation of NFκB, and plasma cell identity. Latest data support the use of genomic profiling to optimize… pic.twitter.com/GLo3OWVuao

— Multiple Myeloma Hub (@MM_Hub) December 7, 2024

CONGRESS | #ASH24 | Joshua Gustine, @MassGeneralNews discusses the impact of prior HDM/ ASCT on the PFS of BCMA-directed CAR T-cell therapies in #MultipleMyeloma. Overall, prior HDM/ASCT was associated with poorer PFS but had no impact on response or OS. The extent of impact… pic.twitter.com/GAJxRVEpBu

— Multiple Myeloma Hub (@MM_Hub) December 7, 2024

CONGRESS | #ASH24 | @RahulBanerjeeMD @UWMedicine @fredhutch discusses the rationale for moving toward urine-free response criteria in #MultipleMyeloma, showing little discordance between urine and urine-free response data, with a higher number of patients being evaluable for… pic.twitter.com/8hQSBc30Ud

— Multiple Myeloma Hub (@MM_Hub) December 7, 2024

CONGRESS | #ASH24 | POSTER | Susan Bal @SusanBal9 @UABDeptMed presents the updated phase I safety and efficacy results for BMS-986393 for RRMM with 1–3 prior regimens.
Single dose BMS-986393 at the RP2D demonstrated and ORR rate of 96% with deepening responses over time. No new… pic.twitter.com/GQLqSY6xDJ

— Multiple Myeloma Hub (@MM_Hub) December 13, 2024

CONGRESS | #ASH24 | POSTER | Mohamad Mohty @Mohty_EBMT Hôpital Saint-Antoine and Sorbonne University presents a poster presentation on the impact of elranatamab on PROs in pts with RRMM, naïve and exposed to BCMA-DT.
Subcutaneous 76 mg elranatamab improves symptoms and overall… pic.twitter.com/zV6lHd0Apf

— Multiple Myeloma Hub (@MM_Hub) December 13, 2024

CONGRESS | #ASH24 | POSTER | Sikander Ailawadhi @MayoClinic presents a poster on the discrepancies in HCPs and patient perspectives on novel therapies for RRMM.
HCPs and patients differ in treatment priorities, particularly around minimization of TRAEs and efficacy, with limited… pic.twitter.com/9iTy9RebcE

— Multiple Myeloma Hub (@MM_Hub) December 13, 2024

CONGRESS | #ASH24 | POSTER | Hira Mian @HiraSMian @McMasterU presents data evaluating a SUD for etentamig (ABBV-383) to reduce CRS rates in RRMM.
Introducing a SUD of 2mg on D1 and a full 60 mg dose on D4, alongside modified dex premedication, reduced CRS incidence and severity.… pic.twitter.com/beb6wzm89P

— Multiple Myeloma Hub (@MM_Hub) December 13, 2024